Specialized Pro-Resolving Mediators (SPMs)

The Idea That Changed Inflammation Research

For most of the twentieth century, inflammation was assumed to fade passively once the trigger disappeared — the fire burns out when the fuel runs low. That turned out to be wrong. Resolution is an active, programmed phase with its own signalling molecules, and those molecules are made from omega-3 fatty acids.

They are the specialized pro-resolving mediators: resolvins (E-series from EPA, D-series from DHA), protectins, maresins, and lipoxins. Each is produced on demand at the site of inflammation and acts through its own receptors.

What they do is qualitatively different from what anti-inflammatory drugs do. NSAIDs and steroids block the inflammatory programme — effective, and also the reason they impair host defence and wound healing. SPMs terminate it: they stop further neutrophil recruitment, drive macrophages to clear debris and dead cells, and return the tissue to baseline without suppressing immunity.

The distinction matters for anyone stacking anti-inflammatories. Chronic low-grade inflammation may be less a matter of too much signal than of failed resolution — a response that never received its stop instruction.

What Humans Actually Have Evidence For

This is where honesty is required, because the marketing runs well ahead of the trials.

SPM levels respond to supplementation. A randomised, double-blind, placebo-controlled study of enriched marine oil supplements found they raised peripheral blood SPM concentrations and measurably reprogrammed host immune responses. That is a real human result and the strongest thing in the category: the supplements do what they claim at the biomarker level.

Clinical outcome data are thin. What is missing is the next step — randomised trials showing that raising SPM concentrations produces better outcomes in a defined condition, at scale. The mechanistic literature is deep and the outcome literature is shallow.

That combination justifies an evidence grade of C and a specific expectation: you are buying a well-characterised biological effect whose clinical value is not yet established.

What You Are Actually Buying

SPM supplements do not contain resolvins. They contain monohydroxylated precursors — chiefly 18-HEPE, 17-HDHA, and 14-HDHA — concentrated from marine oil, which your enzymes convert into the finished mediators. This is a meaningful distinction: the product is an enriched substrate, not the active molecule.

It also explains the pricing. SPM-enriched oils cost several times ordinary fish oil for a fraction of the total omega-3 content.

Fix the base before buying the concentrate. If your EPA/DHA intake is low, you lack the raw material for endogenous SPM production, and omega-3 at a fraction of the cost is the higher-yield intervention. SPM supplements make sense as a layer on top of adequate omega-3 status, not as a substitute for it.

Dosage

Safety

The safety profile is essentially that of the marine oil it is concentrated from: reflux, fishy aftertaste, mild gastrointestinal upset, and the standard bleeding caution alongside anticoagulants. There is no signal of toxicity. What there is instead is absence of long-term data, which is the honest reason for a B safety tier rather than an A.

One genuine pathway interaction is worth knowing: low-dose aspirin acetylates COX-2 and shifts it toward producing aspirin-triggered resolvins. That is a documented mechanism — but aspirin belongs to a physician's risk-benefit calculation, not a supplement stack.

Related Research

• Specialized Pro-Resolving Mediators: Beyond Omega-3
• The Inflammation Resolution Stack: Curcumin + Boswellia + SPMs
• The Inflammation Resolution Protocol